down arrow

Kintara Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US49720K2006
USD
0.82
-0.07 (-7.69%)

Dec 19

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.800.91

52 Week

0.805.50
Valuation
Technical
Day's Volume

CASH

337.23 k

Shareholding (Mar 2025)

FII

0.50%

Held by 11 FIIs

DII

94.4%

Held by 6 DIIs

Promoter

0.00%

What does Kintara Therapeutics, Inc. do?

22-Jun-2025

Kintara Therapeutics, Inc. is a clinical-stage drug development company focused on cancer treatment, with a market cap of $103.60 million and a recent net profit loss of $7 million. The company has no dividend yield and significant negative return on equity.

Overview: <BR>Kintara Therapeutics, Inc. is a clinical-stage drug development company focused on the treatment of cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -7 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 103.60 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.61 <BR>Return on Equity: -209.43% <BR>Price to Book: 10.51<BR><BR>Contact Details: <BR>Address: 12707 High Bluff Drive, Suite 200, SAN DIEGO CA: 92130 <BR>Tel: 1 604 2021384 <BR>Website: https://www.kintara.com/

Read More

Who are in the management team of Kintara Therapeutics, Inc.?

22-Jun-2025

As of March 2022, Kintara Therapeutics, Inc.'s management team includes Mr. Robert Hoffman (Independent Chairman), Mr. Saiid Zarrabian (President and CEO), and Directors Mr. John Liatos, Mr. Keith Murphy, and Mr. Robert Toth. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Kintara Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Robert Hoffman, who serves as the Independent Chairman of the Board.<BR>- Mr. Saiid Zarrabian, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. John Liatos, who is a Director.<BR>- Mr. Keith Murphy, who is also a Director.<BR>- Mr. Robert Toth, who serves as an Independent Director.<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Read More

Is Kintara Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of July 1, 2025, Kintara Therapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, including a mildly bullish MACD and bearish daily moving averages, indicating a lack of strong momentum.

As of 1 July 2025, the technical trend for Kintara Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators showing mixed signals. The MACD is mildly bullish on both weekly and monthly time frames, while the Bollinger Bands indicate a mildly bearish trend weekly and bearish monthly. The daily moving averages are bearish, and the KST shows a mildly bullish signal weekly but bearish monthly. The Dow Theory suggests a mildly bullish stance on the monthly time frame, but no trend is present weekly. Overall, the mixed signals indicate a lack of strong momentum in either direction. Multi-period return data is not available for comparison with the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 127 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.41

stock-summary
Return on Equity

-123.10%

stock-summary
Price to Book

6.52

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-10 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-68.64%
0%
-68.64%
6 Months
-69.68%
0%
-69.68%
1 Year
-79.53%
0%
-79.53%
2 Years
-87.26%
0%
-87.26%
3 Years
-90.18%
0%
-90.18%
4 Years
-99.93%
0%
-99.93%
5 Years
-99.96%
0%
-99.96%

Kintara Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-194.52%
EBIT to Interest (avg)
-12.66
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.61
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
9.80%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
12.05
EV to EBIT
-5.66
EV to EBITDA
-5.68
EV to Capital Employed
-43.60
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-209.43%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (5.1%)

Foreign Institutions

Held by 11 Foreign Institutions (0.5%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -313.04% vs 30.30% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.00",
          "val2": "-2.40",
          "chgp": "-150.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.50",
          "val2": "-2.30",
          "chgp": "-313.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.50",
          "val2": "0.00",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "4.10",
          "val2": "0.00",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.30",
          "val2": "0.00",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.70",
          "val2": "0.00",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.00
-2.40
-150.00%
Interest
0.00
0.00
Exceptional Items
-3.90
0.00
Consolidate Net Profit
-9.50
-2.30
-313.04%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -313.04% vs 30.30% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Change(%)
Net Sales
0.00
0.00
NA
Operating Profit (PBDIT) excl Other Income
-17.50
0.00
NA
Interest
4.10
0.00
NA
Exceptional Items
-0.30
0.00
NA
Consolidate Net Profit
-21.70
0.00
NA
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

Not Applicable: The company has declared_date for only one period

Consolidated Net Profit

Not Applicable: The company has declared_date for only one period

All Annual Resultsstock-summary
stock-summaryCompany CV
About Kintara Therapeutics, Inc. stock-summary
stock-summary
Kintara Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Kintara Therapeutics Inc, formerly DelMar Pharmaceuticals, Inc., is a clinical-stage drug development company focused on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). VAL-083 is being evaluated in a Phase II clinical trial for the treatment of GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. AL-083 is a small-molecule, a deoxyribonucleic acid (DNA) targeting chemotherapeutic. VAL-083 has accessed over 40 Phase I and Phase II clinical trials sponsored by the National Cancer Institute (NCI).
Company Coordinates stock-summary
Company Details
12707 High Bluff Drive, Suite 200 , SAN DIEGO CA : 92130
stock-summary
Tel: 1 604 2021384
stock-summary
https://www.kintara.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."